 |
|
Proton Pump Inhibitor Therapy and Hip Fracture Risk
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: While secondary causes of osteoporosis frequently contribute to hip fractures,1-2 studies of these associations may be hampered by a lack of control for relevant confounding variables. In assessing the association of gastric acid suppression with hip fractures, Dr Yang and colleagues3 did not address vitamin D status as a potential confounder.
The authors hypothesize that gastric acid suppression may impair the release of ionized calcium from calcium salts, leading to calcium malabsorption and impaired skeletal mineralization. However, despite the pandemic of vitamin D insufficiency in adults,4 this vital component of bone health was not considered. There is an inverse relationship between serum 25-hydroxyvitamin D status and parathyroid hormone levels in patients with hip fractures.5 However, Yang et al3 did not provide data regarding the participants' vitamin D status, parathyroid hormone levels, or urinary calcium concentration.
Without these data, it is not clear whether the observed difference in . . . [Full Text of this Article]
Jordan L. Geller, MD
jordan.geller@cshs.org
John S. Adams, MD
Division of Endocrinology
Cedars-Sinai Medical Center
Los Angeles, Calif
RELATED LETTER
Proton Pump Inhibitor Therapy and Hip Fracture Risk—Reply
Yu-Xiao Yang, James D. Lewis, Solomon Epstein, and David C. Metz
JAMA. 2007;297(13):1429-1430.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yu-Xiao Yang, James D. Lewis, Solomon Epstein, and David C. Metz
JAMA. 2006;296(24):2947-2953.
ABSTRACT
| FULL TEXT
|
